Noemi Reguart, Medical Oncologist at Hospital Clinic Barcelona, shared a post on X:
“Osimertinib BEATEN!!
MARIPOSA (Ami + Lazer) shows significant OS (HR 0.75, p<0.005, 3yr 60% vs 51%) and landmark 3-yr icPFS improvement (36% vs 18%)—first combo to show OS superiority over SoC, extending OS beyond 3 years in first line EGFRm NSCLC.”
